Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

14.68
BATS BZX Real-Time Price
As of 9:50am ET
 -0.03 / -0.20%
Today’s Change
14.30
Today|||52-Week Range
44.42
-59.50%
Year-to-Date
Chickasaw Capital Management Llc Buys DowDuPont Inc, Bank of America Corporation, Ban...
Oct 16 / GuruFocus News - Paid Partner Content
Macnealy Hoover Investment Management Inc Buys DowDuPont Inc, JM Smucker Co, Schlumbe...
Oct 10 / GuruFocus News - Paid Partner Content
Iowa State Bank Buys Shire PLC, Workiva Inc, BioTime Inc, Sells E.I. ...
Oct 16 / GuruFocus News - Paid Partner Content
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
Oct 09 / Zacks.com - Paid Partner Content
Pharma Industry Outlook - October 2017
Oct 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allerg...
Oct 06 / Zacks.com - Paid Partner Content
Iowa State Bank Buys Shire PLC, Workiva Inc, BioTime Inc, Sells E.I. ...
Oct 16 / GuruFocus News - Paid Partner Content
Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute
Oct 06 / Zacks.com - Paid Partner Content
Trump Hits Pharma
Oct 16 / TheStreet.com - Paid Partner Content
Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early
Oct 05 / Zacks.com - Paid Partner Content
3 Biotech Values in a Fully Valued Market
Oct 15 / TheStreet.com - Paid Partner Content
Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval
Oct 04 / Zacks.com - Paid Partner Content
3 Biotech Values in a Fully Valued Market
Oct 13 / TheStreet.com - Paid Partner Content
Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg
Oct 04 / Zacks.com - Paid Partner Content
Bridge Creek Capital Management LLC Buys DowDuPont Inc, Henry Schein Inc, Ormat Techn...
Oct 12 / GuruFocus News - Paid Partner Content
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
Oct 04 / Zacks.com - Paid Partner Content
Mylan Gets Complete Response Letter For Biosimilar Neulasta
Oct 11 / Zacks.com - Paid Partner Content